Study design
ADVERSE EVENTS, REPRODUCTIVE SYSTEM DISORDER, DRUG ALLERGIES
Patients with an initial Nugent Score ≥ 7 were informed of the study protocol. Those who met the criteria signed an informed consent form before the trial. Subjects were asked to complete a questionnaire containing information on demographic characteristics, vaginal health status, history of drug allergies, and history of reproductive system disorders. A random number table generated by SPSS 13.0 software was used to randomly assign subjects to the control or probiotic group using a 1:1 ratio. After enrollment, the probiotic group received MET vaginal suppositories (200 mg daily for 7 days) along with oral intake of probiotic solid drinks containing Follow-up visits were performed on day 14, 30, and 90 after the initiation of treatment. The investigator at enrolment distributed the intervention product. At each follow-up visit, the subject’s compliance, frequency of sex, vaginal health, and the occurrence of adverse events (AEs) were assessed by questionnaire. Subjects were required to avoid topical vaginal dosing during menstruation but continue to take the intervention product orally (Study design 